Sarah Middleton

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

Tillotts Pharma AG manufactures pharmaceuticals for treatment of gastrointestinal diseases. The firm specializes in the therapy of the lower gastrointestinal tract. It offers Asacol, Entocort, Colpermin, Tillhepo and VistaPrep. The company was founded in 1986 and is headquartered in Ziefen, Switzerland.

Part of PAION AG, Cenes Ltd. develops treatments for diseases of the central nervous system. The company is based in Histon, UK.

GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom.

3i Private Equity is a private equity firm, founded in 1945. The firm is headquartered in London, United Kingdom with additional offices around the world.

Esperante Ltd. operates as a venture investment company controlled by C&P Group Holdings. The company was founded on April 29, 1986 and is headquartered in Maidenhead, the United Kingdom.

Esperante BV (Esperante) is a Dutch based venture capital firm which was founded by Dean Slagel in 2004. Esperante is a seed investor which invests in emerging biotechnology companies engaged in the development of novel therapeutics in areas of major unmet medical need. The firm has a portfolio of investments across France, the UK and the US. The firm provides investee companies with extended management resources, particularly in business development, as a complement to their financial contribution. They also conduct scientific and intellectual property evaluations using confidential life science industry consultants.

Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom.

Kings' Holdings LLC Owns and operates educational institutions. The company holds and manages Schools and learning facilities. The company was founded in 2004 and it is headquartered in Dubai, United Arab Emirates.

Albion Ventures LLP (Albion Ventures) is a venture capital firm founded in 1996. The firm is headquartered in London.

Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom.

Dragon Hydro Ltd. operates hydropower generation plants. It specializes in development, financing, construction, and operation of hydro power generated plants. The company was founded by Jonathan Mark Bensted and Gary John Markham in 2008 and is headquartered in Wilden, the United Kingdom.

Proveca Ltd. develops pharmaceuticals for children and adults through studies dedicated to providing evidence for the specific use of off-patent medicines. The firm develops medicines for children in the fields of cardiology, neurology, and pain management. The company was founded by Simon Peter Bryson and Helen Margaret Shaw in July 2010 and is headquartered in Warrington, the United Kingdom.

Ferring Pharmaceuticals Ltd. manufactures and produces pharmaceutical products. It offers Zomacton (somatropin) for that treatment of growth failure in children and for girl’s diagnosed with Turners syndrome; GONAPEPTYL (triptorelin), a GnRH agonist that is used for the treatment of children with central precocious puberty; Testim (testosterone gel), a hydroalcoholic topical gel; and PENTASA (mesalazine), which is used for the treatment of inflammatory bowel diseases. The company was founded in 1975 and is headquartered in Middlesex, the United Kingdom.

Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom.

Cisiv Ltd. develops technology solutions for pharmaceutical companies. It offers web-based software platform that allows patient data to be easily captured, analyzed, and shared. The company was founded in 1995 by Dominic Michael Trafford Farmer and Ruth Helen Whittaker and is headquartered in Kingston-upon-Thames, the United Kingdom.

Chonais River Hydro Ltd. operates as a holding company. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Gharagain River Hydro Ltd. operates as a holding company. The company was founded on November 4, 2014 and is headquartered in London, the United Kingdom.

Parkure Ltd. develops and discovers drugs for cure of parkinson's disease . The company was founded by Lysimachos Zografos and is headquartered in Lanarkshire, the United Kingdom.

Alveron Pharma BV is a Dutch company that develops cyclodextrin-based drugs. The company is based in Nijmegen, Netherlands. The company was founded in 2019. Ben Nichols has been the CEO of the company since 2019.

Altacor Ltd. operates as a specialist ophthalmology company develops and markets a portfolio of products in the fields of dry eye, glaucoma and ocular infection. The company was founded by Francesca Elizabeth Crawford and David Francis Alcraft in 2007 and is headquartered in Theale, the United Kingdom.